Get the Stockscreener App
37.99
0.63%
-0.24
After Hours:
37.99
Definium Therapeutics Inc stock is traded at $37.99, with a volume of 1.29M.
It is down -0.63% in the last 24 hours and down -17.66% over the past month.
Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.
See More
Previous Close:
$38.23
Open:
$37.82
24h Volume:
1.29M
Relative Volume:
0.45
Market Cap:
$5.10B
Revenue:
-
Net Income/Loss:
$-237.54M
P/E Ratio:
-15.18
EPS:
-2.5033
Net Cash Flow:
$-145.05M
1W Performance:
-2.34%
1M Performance:
-17.66%
6M Performance:
+107.03%
1Y Performance:
+0.00%
1-Day Range:
$37.68
$38.93
1-Week Range:
$37.32
$39.26
52-Week Range:
$14.62
$49.70
Definium Therapeutics Inc Stock (DFTX) Company Profile
Name
Definium Therapeutics Inc
Sector
Industry
Phone
212-220-6633
Address
ONE WORLD TRADE CENTER, NEW YORK
Compare DFTX vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DFTX
Definium Therapeutics Inc
|
37.99 | 5.14B | 0 | -237.54M | -145.05M | -2.5033 |
VRTX
Vertex Pharmaceuticals Inc
|
521.12 | 134.06B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
807.65 | 83.43B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,002.31 | 63.00B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
135.61 | 56.02B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.68 | 44.44B | 742.00K | -1.37B | -1.07B | -7.0731 |
Definium Therapeutics Inc Stock (DFTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-17-26 | Initiated | Stifel | Buy |
| Apr-10-26 | Initiated | Piper Sandler | Overweight |
| Feb-24-26 | Initiated | Wolfe Research | Outperform |
| Jan-30-26 | Initiated | Jefferies | Buy |
| Oct-13-25 | Initiated | Needham | Buy |
| Aug-04-25 | Resumed | Oppenheimer | Outperform |
| Jan-28-25 | Initiated | Evercore ISI | Outperform |
| Dec-20-24 | Initiated | Chardan Capital Markets | Buy |
| Oct-14-24 | Resumed | Leerink Partners | Outperform |
| Jul-24-24 | Initiated | ROTH MKM | Buy |
| May-29-24 | Initiated | Robert W. Baird | Outperform |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Dec-05-23 | Initiated | Canaccord Genuity | Buy |
| Dec-09-22 | Resumed | ROTH Capital | Buy |
| Nov-16-22 | Initiated | RBC Capital Mkts | Outperform |
| Aug-26-22 | Initiated | Oppenheimer | Outperform |
| Aug-10-22 | Initiated | Cantor Fitzgerald | Overweight |
| May-04-22 | Initiated | ROTH Capital | Buy |
| Jun-28-21 | Initiated | Maxim Group | Buy |
View All
Definium Therapeutics Inc Stock (DFTX) Latest News
DFTXDefinium Therapeutics Inc Revenue Breakdown - Finviz
DFTX Vs CMPS: Which Stock Has More Upside From Trump’s New Psychedelic Therapy Push? - Stocktwits
symbol__ Stock Quote Price and Forecast - CNN
Definium Therapeutics CEO Robert Barrow Sells 19,023 Shares Following 40,000-Share Award - Kalkine Media
Top Definium Therapeutics (DFTX) Competitors 2026 - MarketBeat
Definium Therapeutics Secures Second FDA Breakthrough Therapy Designation for DT120 in MDD - Minichart
Definium Therapeutics Gains FDA Breakthrough for Depression Drug - TipRanks
Definium Therapeutics (DFTX) Gains FDA Breakthrough Therapy Desi - GuruFocus
Definium Therapeutics receives FDA Breakthrough Therapy designation for DT120 ODT in MDD after positive Phase 3 - TradingView
Single LSD tablet in Definium Therapeutics (DFTX) trial shows 12-week benefit in major depression - Stock Titan
Definium Therapeutics Receives Breakthrough Therapy Designation for DT120 (lysergide) Orally Disintegrating Tablet (ODT) in Major Depressive Disorder (MDD) Following Positive Phase 3 Results - Business Wire
Definium Therapeutics Stock (DFTX) Opinions on Analyst Upgrade and Regulatory Progress - Moomoo
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares By Investing.com - Investing.com South Africa
Definium Therapeutics CEO Robert Barrow sells $721,732 in shares - Investing.com
Definium Therapeutics (DFTX) CEO gets 40K-share award, sells stock for taxes - Stock Titan
Definium Therapeutics, Inc. (NASDAQ: DFTX) Stock Price, News & Analysis - Kalkine
Transcript : Definium Therapeutics, Inc.Special Call - marketscreener.com
After $1.23M sale, Definium Therapeutics (DFTX) holder plans another stock trade - Stock Titan
Stifel reiterates Buy on Definium Therapeutics stock, $60 target By Investing.com - Investing.com Nigeria
Stifel reiterates Buy on Definium Therapeutics stock, $60 target - Investing.com
Analysts Offer Insights on Healthcare Companies: Vor Biopharma (VOR), Definium Therapeutics (DFTX) and IDEAYA Biosciences (IDYA) - The Globe and Mail
Definium Therapeutics Announces New Employee Inducement Grants - The Chronicle-Journal
Wells Fargo Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $72 - moomoo.com
Stifel Maintains Definium Therapeutics(DFTX.US) With Buy Rating, Maintains Target Price $60 - Moomoo
Stifel confident in Definium Therapeutics stock after management dinner By Investing.com - Investing.com Nigeria
Stifel confident in Definium Therapeutics stock after management dinner - Investing.com
SW Weekly: Why I Can't Buy Definium Following Phase 3 LSD Readout. (NASDAQ:DFTX) - Seeking Alpha
Definium Therapeutics to Participate at Upcoming Investor Conferences and Events - Business Wire
Certain Common Shares of Definium Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-AUG-2026. - marketscreener.com
Certain Warrants of Definium Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 23-AUG-2026. - marketscreener.com
DRIEHAUS CAPITAL MANAGEMENT LLC Expands Definium Therapeutics In - GuruFocus
Traders Purchase High Volume of Definium Therapeutics Call Options (NASDAQ:DFTX) - MarketBeat
Definium Therapeutics (DFTX) Could Be 22% Undervalued On Positive Phase 3 Voyage Results - Sahm
Total non-current assets of Definium Therapeutics, Inc. – NASDAQ:DFTX - tradingview.com
This Definium Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Sahm
DFTX Stock Clocks Best Day In Over Two Years On 'Best-Case' Clinical Results For Oral Lysergide In Depression - Stocktwits
Definium Therapeutics Posts Strong Phase 3 GAD Data for DT120 - TipRanks
Definium Therapeutics (NASDAQ:DFTX) Coverage Initiated by Analysts at Bank of America - MarketBeat
Definium Therapeutics (DFTX) Is Down 5.6% After Positive Phase 3 GAD Data For DT120 ODT - Sahm
DFTX Initiates Coverage On B of A Securities -- Rating Set to Bu - GuruFocus
BofA initiates Definium Therapeutics stock with buy on psychedelic drug potential - Investing.com Nigeria
Definium Therapeutics (DFTX) Reports Positive Phase 3 GAD Trial Results Amid High Valuation - GuruFocus
DFTX Maintained by Maxim Group -- Price Target Raised to $55 - GuruFocus
Definium Therapeutics Inc Stock (DFTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.00%
0.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):